Emory University’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Emory University’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16,461	Closed	-$2.03M	–	56
2017 Q1	$2.03M	Buy	16,461 +6,939	+73%	+$909K	1.92%	16
2016 Q4	$1.3M	Buy	+9,522	New	+$1.69M	1.28%	42
2015 Q2	–	Sell	-4,526	Closed	-$1.05M	–	23
2015 Q1	$1.05M	Buy	+4,526	New	+$1.09M	1.98%	5

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Emory University's BLCM Position: Q2 2017 in Review

Emory University sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 16,461 shares — an estimated $2.03M sold.

Emory University first reported a position in BLCM in Q1 2015 and held it in 3 quarters. The position peaked at $2.03M in Q1 2017. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

Emory University reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Emory University sold 16,461 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $2.03M.
Emory University first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
Emory University's Bellicum Pharmaceuticals, Inc. position peaked at $2.03M in Q1 2017.
84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Emory University's 13F filing for Q2 2017, filed 10 Aug 2017.